Multimodal management and outcome of pediatric and adolescent malignant central nervous system tumors: A single-center retrospective study

Abstract

Objective: There is a paucity of real-world evidence in the Indian context to address the outcome of primary brain tumors (PBTs) in children. This study aimed to describe the demographic profile, clinical characteristics, and histological features of PBTs based on the 2016 World Health Organization classification, assess the efficacy of treatment methods, and identify the factors that influence the outcome.

Methodology: This is a single-institution, hospital-based study. Data were collected for pediatric patients aged 0-19 years, from September 2001 to May 2023 (22 years), who were diagnosed with malignant PBTs. Patients with radiologically or histologically proven tumors were included. Those with metastatic disease to the central nervous system were excluded. The overall survival (OS) and recurrence-free survival (RFS) were estimated using the Kaplan-Meier method.

Results: A total of 251 patients with pediatric brain tumors were included in this analysis. The mean age was 9.10 ± 5.54 years. The male-to-female ratio was 1.20:1. In this cohort, the most common histologies were medulloblastoma and astrocytoma. The mean survival of all patients with PBTs was 141.00 ± 7.90 months with 1-, 3-, and 8-year OS rates of 79.00%, 67.00%, and 60.00%, respectively. Medulloblastoma had 1-, 3-, and 8-year OS rates of 81.00%, 72.00%, and 65.00%, respectively. The 1-year OS rates for glioblastoma and brainstem glioma were 46.00% and 45.00%, respectively. Complete tumoral resection showed longer survival than lesser degrees of resection (p = 0.001). Embryonal tumors (ETs) had a better RFS of 133.60 ± 12.70 months (p ≤ 0.001).

Conclusion: ETs have a better prognosis than glial tumors. With an improved OS, the surgical resection extent has a favorable outcome. As a chemosensitive tumor, medulloblastoma benefits most from systemic treatment and responds well to a multimodal approach.

Keywords

epidemiology / genetic predisposition / symptoms and signs / malignant primary brain tumors / multimodal treatments / patient outcome assessment

References

[1] Steliarova-Foucher E , Colombet M , Ries LAG , et al. International incidence of childhood cancer, 2001-10: a population-based registry study. Lancet Oncol. 2017; 18 (6): 719- 731.

[2] Subramanian S , Ahmad T , et al. Childhood brain tumors[Internet]. In: StatPearls: StatPearls Publishing; 2023.

[3] Ganguly S , Kinsey S , Bakhshi S . Childhood cancer in India. Cancer Epidemiol. 2021; 71 (Pt B): 101679.

[4] Miller KD , Ostrom QT , Kruchko C , et al. Brain and other central nervous system tumor statistics, 2021. CA Cancer J Clin. 2021; 71 (5): 381- 406.

[5] Ostrom QT , Price M , Ryan K , et al. CBTRUS statistical report: pediatric brain tumor foundation childhood and adolescent primary brain and other central nervous system tumors diagnosed in the United States in 2014-2018. Neuro Oncol. 2022; 24 (Suppl 3): iii1- iii38.

[6] Yang W , Cai Y , Chen J , et al. Epidemiological characteristics, clinical presentations, and prognoses of pediatric brain tumors: experiences of National Center for Children's Health. Front Oncol. 2023; 13: 1067858.

[7] Hall EJ , Wuu CS . Radiation-induced second cancers: the impact of 3D-CRT and IMRT. Int J Radiat Oncol Biol Phys. 2003; 56 (1): 83- 88.

[8] Teoh M , Clark CH , Wood K , Whitaker S , Nisbet A . Volumetric modulated arc therapy: a review of current literature and clinical use in practice. Br J Radiol. 2011; 84 (1007): 967- 996.

[9] Tarbell NJ , Friedman H , Polkinghorn WR , et al. High-risk medulloblastoma: a pediatric oncology group randomized trial of chemotherapy before or after radiation therapy (POG 9031). J Clin Oncol. 2013; 31 (23): 2936- 2941.

[10] Stupp R , Mason WP , van den Bent MJ , et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005; 352 (10): 987- 996.

[11] Geyer JR , Sposto R , Jennings M , et al. Multiagent chemotherapy and deferred radiotherapy in infants with malignant brain tumors: a report from the Children's Cancer Group. J Clin Oncol. 2005; 23 (30): 7621- 7631.

[12] Reddy AT , Strother DR , Judkins AR , et al. Efficacy of high-dose chemotherapy and three-dimensional conformal radiation for atypical teratoid/rhabdoid tumor: a report from the Children's Oncology Group Trial ACNS0333. J Clin Oncol. 2020; 38 (11): 1175- 1185.

[13] Strother DR , Lafay-Cousin L , Boyett JM , et al. Benefit from prolonged dose-intensive chemotherapy for infants with malignant brain tumors is restricted to patients with ependymoma: a report of the Pediatric Oncology Group randomized controlled trial 9233/34. Neuro Oncol. 2014; 16 (3): 457- 465.

[14] Smith A , Onar-Thomas A , Ellison D , et al. EPEN-54. ACNS0831, phase III randomized trial of post-radiation chemotherapy in patients with newly diagnosed ependymoma ages 1 to 21 years. Neuro Oncol. 2020; 22 (Suppl 3): iii318- iii319.

[15] Cohen BH , Geyer JR , Miller DC , et al. Pilot study of intensive chemotherapy with peripheral hematopoietic cell support for children less than 3 years of age with malignant brain tumors, the CCG-99703 phase I/II study. A report from the Children's Oncology Group. Pediatr Neurol. 2015; 53 (1): 31- 46.

[16] Robinson GW , Rudneva VA , Buchhalter I , et al. Risk-adapted therapy for young children with medulloblastoma (SJYC07): therapeutic and molecular outcomes from a multicentre, phase 2 trial. Lancet Oncol. 2018; 19 (6): 768- 784.

[17] Shah HC , Ubhale BP , Shah JK . Demographic and histopathologic profile of pediatric brain tumors: a hospital-based study. South Asian J Cancer. 2015; 4 (3): 146- 148.

[18] Asirvatham JR , Deepti AN , Chyne R , et al. Pediatric tumors of the central nervous system: a retrospective study of 1,043 cases from a tertiary care center in South India. Childs Nerv Syst. 2011; 27 (8): 1257- 1263.

[19] Stanić D , Grujičić D , Pekmezović T , et al. Clinical profile, treatment and outcome of pediatric brain tumors in Serbia in a 10-year period: a national referral institution experience. PLoS One. 2021; 16 (10): e0259095.

[20] Harmouch A , Taleb M , Lasseini A , Maher M , Sefiani S . Epidemiology of pediatric primary tumors of the nervous system: a retrospective study of 633 cases from a single Moroccan institution. Neurochirurgie. 2012; 58 (1): 14- 18.

[21] Santos MM , Faria CC , Miguéns J . Pediatric central nervous system tumors: review of a single Portuguese institution. Childs Nerv Syst. 2016; 32 (7): 1227- 1236.

[22] Nasir S , Jamila B , Khaleeq S . A retrospective study of primary brain tumors in children under 14 years of age at PIMS, Islamabad. Asian Pac J Cancer Prev. 2010; 11 (5): 1225- 1227.

[23] Liu SJ , Aw NMY , Lim MJR , et al. Paediatric brain tumours in Singapore: a 15-year epidemiological and outcome study. J Clin Neurosci. 2022; 101: 154- 161.

[24] Makino K , Nakamura H , Yano S , Kuratsu J. , Population-based epidemiological study of primary intracranial tumors in childhood. Childs Nerv Syst. 2010; 26 (8): 1029- 1034.

[25] Govindan A , Parambil RM , Alapatt JP . Pediatric intracranial tumors over a 5-year period in a tertiary care center of North Kerala, India: a retrospective analysis. Asian J Neurosurg. 2018; 13 (4): 1112- 1117.

[26] Bodeliwala S , Kumar V , Singh D . Neonatal brain tumors: a review. J Neonatal Surg. 2017; 6 (2): 30.

[27] Ghodsi S , Habibi Z , Hanaei S , Moradi E , Nejat F . Brain tumors in infants. J Pediatr Neurosci. 2015; 10 (4): 335- 340.

[28] Haddad SF , Menezes AH , Bell WE , Godersky JC , Afifi AK , Bale JF . Brain tumors occurring before 1 year of age: a retrospective review of 22 cases in an 11-year period (1977-1987). Neurosurgery. 1991; 29 (1): 8- 13.

[29] Hernáiz Driever P , von Hornstein S , Pietsch T , et al. Natural history and management of low-grade glioma in NF-1 children. JNO. 2010; 100 (2): 199- 207.

[30] Rodriguez FJ , Perry A , Gutmann DH , et al. Gliomas in neurofibromatosis type 1: a clinicopathologic study of 100 patients. J Neuropathol Exp Neurol. 2008; 67 (3): 240- 249.

[31] Spyris CD , Castellino RC , Schniederjan MJ , Kadom N . High-grade gliomas in children with neurofibromatosis type 1: literature review and illustrative cases. Am J Neuroradiol. 2019; 40 (2): 366- 369.

[32] Garibotto F , Madia F , Milanaccio C , et al. Pediatric diffuse midline gliomas H3 K27M-mutant and non-histone mutant midline high-grade gliomas in neurofibromatosis type 1 in comparison with non-syndromic children: a single-center pilot study. Front Oncol. 2020; 10: 795.

[33] Evans D , Farndon P , Burnell L , Gattamaneni H , Birch J . The incidence of Gorlin syndrome in 173 consecutive cases of medulloblastoma. Br J Cancer. 1991; 64: 959- 961.

[34] Foulkes WD , Kamihara J , Evans DGR , et al. Cancer surveillance in Gorlin syndrome and rhabdoid tumor predisposition syndrome. Clin Cancer Res. 2017; 23 (12): e62- e67.

[35] Hirata K , Muroi A , Tsurubuchi T , et al. Time to diagnosis and clinical characteristics in pediatric brain tumor patients. Childs Nerv Syst. 2020; 36 (9): 2047- 2054.

[36] Wilne S , Collier J , Kennedy C , Koller K , Grundy R , Walker D . Presentation of childhood CNS tumours: a systematic review and meta-analysis. Lancet Oncol. 2007; 8 (8): 685- 695.

[37] Bhattacharyya M , Paul M , Hazarika M , Kalita AK , Baishya N , Kalita MK . Primary brain tumours in pediatric age group and the patterns of care in patients of the north-eastern region of India: a hospital based retrospective analysis. Natl J Med Res. 2020; 10 (2): 60- 63.

[38] Mehta DP , Anand AS , Patel D , et al. Demographic and histopathologic profile of pediatric patients with primary brain tumors attending a regional cancer center. Indian J Med Paediatr Oncol. 2019; 40 (Suppl 1): S65- S69.

[39] Yao B , Wang H , Wu X , et al. A system review of central nervous system tumors on children in China: epidemiology and clinical characteristics. BMC Cancer. 2024; 24 (1): 138.

[40] Suresh S , Srinivasan A , Scott J , Rao S , Chidambaram B , Chandrasekar S . Profile and outcome of pediatric brain tumors—experience from a tertiary care pediatric oncology unit in South India. J Pediatr Neurosci. 2017; 12 (3): 237- 244.

[41] Stagno V , Mugamba J , Ssenyonga P , Kaaya BN , Warf BC . Presentation, pathology, and treatment outcome of brain tumors in 172 consecutive children at CURE Children's Hospital of Uganda. The predominance of the visible diagnosis and the uncertainties of epidemiology in sub-Saharan Africa. Childs Nerv Syst. 2014; 30 (1): 137- 146.

[42] Jain A , Sharma M , Suri V , et al. Spectrum of pediatric brain tumors in India: a multi-institutional study. Neurol India. 2011; 59 (2): 208- 211.

[43] Das U , Appaji L , Kumari BSA , et al. Spectrum of pediatric brain tumors: a report of 341 cases from a tertiary cancer center in India. Indian J Pediatrics. 2014; 81 (10): 1089- 1091.

[44] Karkouri M , Zafad S , Khattab M , et al. Epidemiologic profile of pediatric brain tumors in Morocco. Childs Nerv Syst. 2010; 26 (8): 1021- 1027.

[45] Wisoff JH , Sanford RA , Heier LA , et al. Primary neurosurgery for pediatric low-grade gliomas: a prospective multi-institutional study from the Children's Oncology Group. Neurosurgery. 2011; 68 (6): 1548- 1555.

[46] Azad TD , Shrestha RK , Vaca S , et al. Pediatric central nervous system tumors in Nepal: retrospective analysis and literature review of low- and middle-income countries. World Neurosurg. 2015; 84 (6): 1832- 1837.

RIGHTS & PERMISSIONS

The Author(s). Malignancy Spectrum published by John Wiley & Sons Australia, Ltd on behalf of Higher Education Press.